Results from the use of BrafV600EInk4a-Arf knock-out murine allografts and BRAFV600E + CDKN2A-deficient human glioma xenografts demonstrated the anti-tumor activity of PLX4720 [14, 15], a tool compound of the FDA-approved BRAFV600E-inhibitor vemurafenib. This evidence concerns the gene CDKN2A and central nervous system cancer.